Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biotechnology

- PMLiVE

AbbVie teams up with charities to raise awareness of bronchiolitis

Most common cause of infant hospital admissions in winter

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

- PMLiVE

Amgen biosimilar matches AbbVie’s Humira in psoriasis trial

ABP 501 set to compete with world’s biggest-selling drug

- PMLiVE

Boehringer Ingelheim launches Sound Challenge app

Looks to raise awareness of rare lung disease IPF

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

AbbVie forges $1.5bn ageing disease alliance with Calico

Pharma company partners with Google’s health research business

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

AbbVie begins ‘first-of-its-kind’ hep C charity pilot

Will work with Addaction Cornwall and The Hepatitis C Trust

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

- PMLiVE

AbbVie coaxes Shire into discussions with sweetened offer

Raises takeover bid to $53bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links